Nasus Pharma (NSRX) vs Scilex (SCLX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Nasus Pharma (NSRX) has outperformed Scilex (SCLX) over the past year, losing 50.1% versus a loss of 73.0%. Nasus Pharma is the larger company by market cap ($42.5 million vs $20.8 million), about 2.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NSRX | SCLX |
|---|---|---|
| Share price | $3.63 | $2.96 |
| Market cap | $42.52M | $20.82M |
| 1-day change | -3.84% | -15.19% |
| YTD return | -60.33% | -61.03% |
| 1-year return | -50.07% | -72.96% |
| 5-year return | — | -98.65% |
| Forward P/E | — | 4.05 |
| EPS (TTM) | $-1.20 | $-49.70 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $9.50 | $16.81 |
| 52-week low | $1.98 | $2.62 |
| Distance from 52-week high | -61.79% | -82.39% |
| Analyst consensus | buy | — |
| Avg. price target upside | +441.87% | — |
| Average volume | 16.09K | 54.58K |
| Shares outstanding | 11.71M | 7.03M |
| Employees | 7 | 34 |
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - General | Drug Manufacturers - General |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Nasus Pharma is about 2.0 times larger than Scilex by market value ($42.52M vs $20.82M).
- NSRX has outperformed SCLX by 22.9 percentage points over the past year.
About Nasus Pharma
NSRX stock →Nasus Pharma Ltd., a clinical-stage specialty pharmaceutical company focused on the development of intranasal drugs to treat emergency medical conditions. It offers Powder-Based Intranasal (PBI) products to address acute medical conditions and public health threats.
Healthcare · Drug Manufacturers - General · 7 employees
About Scilex
SCLX stock →Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.
Healthcare · Drug Manufacturers - General · 34 employees
NSRX vs SCLX FAQ
Which is bigger, Nasus Pharma or Scilex?
Nasus Pharma (NSRX) is larger, with a market capitalization of $42.52M compared with $20.82M for Scilex (SCLX).
Which stock has performed better over the past year, NSRX or SCLX?
NSRX returned -50.07% over the past 12 months, compared with -72.96% for SCLX (price return, excluding dividends). Past performance does not predict future results.
Are Nasus Pharma and Scilex in the same industry?
Yes. Both are classified in the Drug Manufacturers - General industry within the Healthcare sector.